Cantor Fitzgerald Reiterates Overweight on Ascendis Pharma, Maintains $152 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Ascendis Pharma (NASDAQ:ASND) and maintained a price target of $152.
December 20, 2023 | 3:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Li Watsek reaffirmed an Overweight rating on Ascendis Pharma with a $152 price target.
The reiteration of an Overweight rating and the maintenance of a high price target by a reputable analyst could lead to increased investor confidence and a potential short-term positive impact on ASND's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100